| Filed On | Filing |
|---|---|
| 10 Nov 2026 |
8-K: Results of Operations and Financial Condition
Continued Strong Performance Driven by Growth in Acthar® Gel1 and XIAFLEX®2 |
| 11 Aug 2026 |
8-K: Results of Operations and Financial Condition
Strong Performance Driven by Growth in Acthar® Gel1 and XIAFLEX®2 |
| 03 Aug 2026 |
8-K: Other Events
On July 31, 2026, Keenova Therapeutics plc (the “Company”) closed the previously disclosed sale of its Percocet and Endocet businesses (the “Business”) to Par Health, Inc (“Par Health”). Consideration for the transaction is expected to t... |
| 08 Jul 2026 |
8-K: Regulation FD Disclosure; Other Events
Keenova Announces Positive Phase 3 Results in Clinical Trial of XIAFLEX® (collagenase clostridium histolyticum) for Treating Plantar Fibromatosis |
| 15 Jun 2026 |
8-K: Other Events
On June 13, 2026, Keenova Therapeutics plc (“Keenova”) entered into a purchase agreement with Par Health, Inc. (the “Purchaser”), pursuant to which Keenova has agreed to sell its Percocet and Endocet businesses (the “Business”) to Purcha... |
| 03 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
Each of the items listed below was submitted to a vote of shareholders at the 2026 Annual General Meeting of Shareholders (the “2026 AGM”) on June 2, 2026 and is described in more detail in Keenova Therapeutics plc’s (the “Company”) defi... |
| 12 May 2026 |
8-K: Results of Operations and Financial Condition
Strong First-Quarter Performance Driven by Acthar® Gel1 and XIAFLEX®2 |
| 31 Mar 2026 |
8-K: Results of Operations and Financial Condition; Other Events
The following unaudited non-GAAP pro forma combined net sales and adjusted EBITDA are derived from the historical consolidated financial statements of Keenova Therapeutics plc (formerly known as Mallinckrodt plc, “Keenova” or the “Compan... |
| 24 Feb 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
This FOURTH AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Agreement”), is entered into on February 23, 2026 (the “Effective Date”), by and between ST Shared Services LLC, a Delaware limited liability company, or any successor thereto ... |
| 20 Feb 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
PERFORMANCE RESTRICTED UNIT AWARD (“Award”) granted on ______, ___ (the “Grant Date”). |
| 10 Nov 2025 |
8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement +2 more
Ernst & Young LLP (EY) prepared the attached Report only for Mallinckrodt Plc (the "Client") pursuant to an agreement solely between EY and Client. EY did not perform its services on behalf of or to serve the needs of any other person or... |
| 10 Nov 2025 |
8-K: Results of Operations and Financial Condition
Delivers Third Quarter Net Sales of $753.1 Million, Driven by Acthar® Gel (repository corticotropin injection) Growth and the Inclusion of Two Months of Endo Product Net Sales |
| 07 Nov 2025 |
8-K: Amendments to Articles/Bylaws; Change in Fiscal Year
On November 7, 2025, Mallinckrodt plc (the “Company”) determined to change the Company’s fiscal year end from a 52-53 week year ending on the last Friday of December to a calendar year ending on December 31. The Company will make the fis... |
| 30 Oct 2025 |
8-K: Regulation FD Disclosure
PLEASE COMPLETE YOUR CERTIFICATION FORM AS SOON AS POSSIBLE—IF MALLINCKRODT HAS NOT RECEIVED SUFFICIENT VALID CERTIFICATION FORMS FROM QUALIFIED SHAREHOLDERS BY NOVEMBER 7, 2025, AT 5:30 P.M. (EASTERN TIME IN THE UNITED STATES) (OR SUCH ... |
| 24 Oct 2025 |
8-K: Other Events
To: The Holders of the 2025 Preferred Shares (as defined below) as at the Record Date (as defined below) |
| 15 Oct 2025 |
8-K: Material Modification to Rights of Security Holders; Amendments to Articles/Bylaws; Change in Fiscal Year +1 more
The name of the Company is Mallinckrodt public limited company. |
| 09 Oct 2025 |
8-K: Submission of Matters to a Vote of Security Holders
On October 8, 2025, Mallinckrodt plc (“Mallinckrodt” or the “Company”) held an extraordinary general meeting of shareholders (the “EGM”) to vote on matters outlined in Mallinckrodt’s proxy statement on Schedule 14A, filed with the U.S. S... |
| 06 Oct 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
1 The supplemental financial information contains adjusted earnings before interest, taxes, depreciation, and amortization (“EBITDA”), which is considered a “Non GAAP” financial measure under the applicable U.S. Securities and Exchange C... |
| 22 Sep 2025 |
8-K: Regulation FD Disclosure
DUBLIN, September 22, 2025 – Mallinckrodt plc today announced the appointment of Dr. Marek J. Honczarenko as Executive Vice President and Chief Scientific Officer, effective September 29, 2025. Dr. Honczarenko, currently the SVP and Head... |
| 25 Aug 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
Loading...